【摘要】：目的:研究枸櫞酸坦度螺酮聯(lián)合5-羥色胺再攝取抑制劑(SSRIs)治療伴焦慮狀態(tài)的抑郁癥患者的療效和對(duì)性功能的影響。方法:將符合入組標(biāo)準(zhǔn)的100例患者隨機(jī)分為實(shí)驗(yàn)組(50例)和對(duì)照組(50例),對(duì)照組予以口服SSRIs,實(shí)驗(yàn)組在此基礎(chǔ)上予以口服枸櫞酸坦度螺酮,2組均連續(xù)治療6周,在入組時(shí)及治療第2、4、6周后分別采用漢密爾頓抑郁量表(HAMD)、漢密爾頓焦慮量表(HAMA)評(píng)定2組療效,并根據(jù)HAMD第14項(xiàng)評(píng)定藥物對(duì)性功能的影響情況。結(jié)果:治療的第2、4、6周,2組的HAMD評(píng)分、HAMA評(píng)分均有降低,而實(shí)驗(yàn)組明顯低于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。服藥期間對(duì)照組的性功能障礙發(fā)生率明顯高于實(shí)驗(yàn)組。結(jié)論:枸櫞酸坦度螺酮聯(lián)合SSRIs治療伴有焦慮狀態(tài)的抑郁癥患者具有療效高、對(duì)性功能影響小的優(yōu)點(diǎn),值得推廣。
[Abstract]:Aim: to study the efficacy and sexual function of tandoxone citrate combined with serotonin reuptake inhibitor (SSRIs) in the treatment of depression with anxiety. Methods: 100 patients were randomly divided into two groups: experimental group (n = 50) and control group (n = 50). The control group was treated with oral SSRIs, for 6 weeks. Hamilton Depression scale (HAMD),) and Hamilton anxiety scale (HAMA) were used to evaluate the efficacy of the two groups at the time of entry and 6 weeks after treatment, and the effects of drugs on sexual function were evaluated according to item 14 of HAMD. Results: the HAMD scores of the two groups were significantly lower than those of the control group at the 2nd week of the 4th week (P0.05), while the Hama scores in the experimental group were significantly lower than those in the control group (P0.05). The incidence of sexual dysfunction in the control group was significantly higher than that in the experimental group. Conclusion: the combination of tandoxone citrate and SSRIs in the treatment of depression with anxiety state has the advantages of high curative effect and little influence on sexual function, so it is worth popularizing.
【作者單位】： 南昌大學(xué)第一附屬醫(yī)院心身科;
【分類號(hào)】：R749.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 郝軍鋒;王美;劉聯(lián)琦;周平;馮志娟;廖艷輝;;SSRIs和非SSRIs類藥物對(duì)住院患者焦慮和抑郁情緒改善情況的比較[J];國(guó)際精神病學(xué)雜志;2013年01期

2 殷青云,蘇林雁,李雪榮;SSRIs在兒童及青少年精神障礙中的應(yīng)用[J];臨床精神醫(yī)學(xué)雜志;2003年06期

3 劉同洲;選擇性五羥色胺再攝取抑制劑(SSRIs)及其在精神科臨床的應(yīng)用[J];山東精神醫(yī)學(xué);2003年04期

4 周璐敏;楊燕;楊金祥;;選擇性血清素重?cái)z取抑制藥(SSRIs)有增加自殺風(fēng)險(xiǎn)[J];中國(guó)藥師;2010年05期

5 唐麗甌;劉暉;馮衛(wèi)華;王海霞;;SSRIs相關(guān)性低鈉血癥及橋腦中央髓鞘溶解癥3例報(bào)告[J];山東醫(yī)藥;2013年18期

6 張紅芳;;我院SSRIs類抗抑郁藥的應(yīng)用與臨床評(píng)價(jià)[J];基層醫(yī)學(xué)論壇;2009年07期

7 李素水;宋麗華;王靈君;孫志剛;王霞;杜義敏;;SSRIs類抗抑郁劑對(duì)青少年腦神經(jīng)元發(fā)育影響的研究進(jìn)展[J];中國(guó)健康心理學(xué)雜志;2013年10期

8 武寧強(qiáng);;選擇性五羥色胺再攝取抑制劑禁用于兒童和青少年抑郁治療的研究進(jìn)展[J];中國(guó)民康醫(yī)學(xué);2011年20期

9 薛耀;;解郁泄熱方治療SSRIs類抗抑郁藥性功能障礙副反應(yīng)臨床觀察[J];新中醫(yī);2014年04期

10 張丁丁;;SSRIs并不增加青少年抑郁癥患者的自殺行為[J];國(guó)外醫(yī)學(xué)情報(bào);2006年03期

相關(guān)會(huì)議論文 前6條

1 Xin Li;Tao Yu;Xueli Sun;Guang He;;SLC17A7 gene may be the indicator of SSRIs treatment response in the Chinese Han popultaion[A];第十二次全國(guó)醫(yī)學(xué)遺傳學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2014年

2 李e，

本文編號(hào)：2205383